Share
Share
Biliary atresia (BA) is a severe pediatric liver disease resulting in obliteration of the extrahepatic biliary tree. BA presents within the first few months of life as either an isolated finding or with additional features. The cause of isolated BA is unknown, with evidence for infectious, environmental, and genetic risk factors described. However, to date, there are no definitive causal genes identified for isolated BA in humans, and the question of whether single gene defects play a major role remains open. We performed exome-sequencing in 101 North American patients of European descent with isolated BA (including 30 parent-child trios) and considered several experimental designs to identify potentially deleterious protein-altering variants that may be involved in the disease. In a case-only analysis, we did not identify genes with variants shared among more than two probands, and burden tests of rare variants using a case-case control design did not yield significant results. In the trio analysis of 30 families (patient and parent trios), we identified 66 new variants in 66 genes including potentially deleterious variants in STIP1 and REV1. STIP1 is a chaperone for the heat-shock protein, HSP90, and has been shown to have diverse functions in yeast, flies and mammals, including stress-responses. REV1 is known to be a key player in DNA repair pathway and to interact with HSP90. In conclusion, our results do not support the hypothesis that a simple genetic model is responsible for the majority of cases of isolated BA. Our finding of de novo variants in genes linked to evolutionarily conserved stress responses (STIP1 and REV1) suggests that exploration of how genetic susceptibility and environmental exposure may interact to cause BA is warranted.
December 5, 2024 — Arbor Research Collaborative for Health is proud to announce an innovative collaboration with the Nephrology Associates of Northern Illinois and Indiana (NANI), the largest private nephrology practice in the United States. This partnership marks a significant milestone in advancing chronic kidney disease (CKD) research and management by leveraging NANI’s extensive patient-level […]
Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal […]
The Health Resources and Services Administration (HRSA) has selected Arbor Research Collaborative for Health (Arbor Research) as one of 14 organizations who will lead the modernization of the Organ Procurement and Transplantation Network (OPTN). Arbor Research received one of the five initial efforts, focusing on improving patient safety and policy compliance systems and processes overseen […]
Arbor Research Collaborative for Health (Arbor Research) is proud to announce that its wholly-owned, small-business subsidiary, Arbor Research LLC, received its first competitive prime contract award. The award expands the organization’s 25-year history doing mission-impactful work in chronic disease and beyond. Arbor Research was awarded the National Cancer Institute (NCI) Center for Global Health (CGH) […]